America’s Comeback as the Global Leader in Medical Research
TL;DR
RFK Jr. argues the U.S. must reclaim its lead in clinical trials and medical innovation, warning that China is ahead in early-stage testing and that Chinese firms accounted for nearly half of global pharma licensing deals in 2025. He outlines Trump-era reforms across FDA, NIH, ONC and ARPA-H to accelerate development while preserving safety, and calls for broad collaboration among researchers, health systems, tech companies and regulators to restore America’s competitive edge and patient access to new therapies.
Topics:businesspolitics#china-competition#clinical-research#fda-nih-arpa-h#medical-innovation#politics#us-leadership
- ROBERT F. KENNEDY JR.: The future of medicine should be built in America Fox News
- China closing in but US leads in biotech quality, commercial reach, survey finds Reuters
- Don’t restrict Chinese biotech The Economist
- China is quietly taking control of US medicine. We must stop helping it. The Hill
- Post-Hoc Live: Are the China hawks winning? Endpoints News
Want the full story? Read the original reporting
Read on Fox News